Expertise in
12
conditions

Alessandro Pulsoni

Latina, IT 
Expertise in
12
conditions
Latina, IT 

Overview

Alessandro Pulsoni practices practicing medicine in Latina, Italy.

Mr. Pulsoni is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Hairy Cell Leukemia (HCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Latina, Italy
Other Locations
Rome, Italy
Sapienza, Italy
Trieste, Italy
Reggio Nell'emilia, Italy
Bologna, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: R2-MANT, R-MANT
Study Phase: Phase 3
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
Study Phase: Phase 3
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Other
Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study
Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study
Enrollment Status: Terminated
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drugs: Idelalisib, Obinutuzumab
Study Phase: Phase 2
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
Enrollment Status: Unknown
Publish Date: December 14, 2023
Intervention Type: Drug, Other
Study Drug: BEAM
Study Phase: Phase 3
A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas
A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas
Enrollment Status: Completed
Publish Date: March 31, 2023
Intervention Type: Drug
Study Drugs: Ledipasvir, Sofosbuvir, Velpatasvir
Study Phase: Phase 2
Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): an Observational Retrospective Multicentre Study on Patients Previously Registered in GIMEMA Clinical Trials
Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): an Observational Retrospective Multicentre Study on Patients Previously Registered in GIMEMA Clinical Trials
Enrollment Status: Terminated
Publish Date: October 26, 2022
Intervention Type: Other
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Drugs: R-CHOP or R-bendamustine, Observation, Maintenance Weekly x4, Ibritumomab Tiuxetan + Maintenance, Standard Maintenance
Study Phase: Phase 3
View 9 Less Clinical Trials

111 Total Publications

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.
Journal: British journal of haematology
Published: May 16, 2026

Frequently Asked Questions about Alessandro Pulsoni

Is Alessandro Pulsoni a top-rated expert for Follicular Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alessandro Pulsoni is classified as an Elite expert for Follicular Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alessandro Pulsoni participate in research or clinical trials?

Yes. Alessandro Pulsoni has published 111 articles and abstracts on conditions like Follicular Lymphoma. You can view a list of Alessandro Pulsoni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pulsoni's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile